

PART V. DEFENDANTS' WITNESSES AND SUMMARY OF THEIR TESTIMONY AND DEPOSITION DESIGNATIONS

Defendants intend to call the following witnesses and anticipate they will testify as follows:

A. Will Call for Live Testimony

Witness	Summary of Testimony
Jeffery Lewis c/o McCarter & English LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102	Mr. Lewis is the Senior Vice President of Engineering at Geomni Inc. He has worked for Defendants in various capacities and positions since 1997. He may testify about his professional background; the operation, functionality, and use of the Accused Products and related systems; research, design, and development of the Accused Products and related systems; the architecture of the Accused Products and related systems; the origin, creation, engineering, development, compilation, storage, location, execution, and use of Defendants' software and source code; documentation concerning the Accused Products and related systems; the Xactimate platform, embedded modules and features thereof, and third-party integrations therewith; historic capabilities, functions, and features of Xactimate; the relationship and interactions between and among Defendants, EagleView, Pictometry, and EagleView Technology Corporation; facts and circumstances underlying and supporting Defendants' positions, contentions, and arguments that the Defendants do not infringe any Asserted Claim of any Asserted Patent. He may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding other subject matter about which he testified at his deposition.

Witness	Summary of Testimony
<p>Edmund Webecke</p> <p>c/o McCarter & English LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102</p>	<p>Mr. Webecke is the President of Verisk 3E. Mr. Webecke may testify regarding his professional background; sales and pricing with regard to the products that are the subject of this case; the development of Defendants' products; the Accused Products in this case; Defendants' customers and customer satisfaction; the operations of and strategies relating to Defendants' businesses; the development and execution of marketing, advertising, and promotion strategies by Defendants; the relationship and interactions between and among Defendants, EagleView, Pictometry, and EagleView Technology Corporation; the dates and circumstances related to when and how Defendants first learned of the Asserted Patents; the dates and circumstances related to when and how Defendants first learned of EagleView; the products, including those of Defendants, that compete with EagleView and/or Pictometry products; presentations, meetings, and discussions regarding EagleView, Pictometry, and/or EagleView Technology Corporation, their products, and/or the Asserted Patents; the corporate structure of the Defendants; the practice and procedures of Defendants for assessing patent infringement risks; business relationships concerning the Accused Products; EagleView's representations of infringement and non-infringement, and Defendants' actions relating to those representations; and Verisk's and/or Xactware's contemplated acquisition of or merger with EagleView, Pictometry, and/or EagleView Technology Corporation. Mr. Webecke may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding other subject matter about which he testified at his deposition.</p>

B. May Call for Live Testimony or by Deposition

Witness	Summary of Testimony
<p>Michael Fulton</p> <p>c/o McCarter & English LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102</p>	<p>Mr. Fulton is the President of Xactware Solutions. He began his career as a self-employed general contractor before joining Xactware in 1992. Mr. Fulton may testify regarding his professional background; sales and pricing with regard to the products that are the subject of this case; the development of Defendants' products; the Accused Products in this case; Defendants' customers and customer satisfaction; the operations of and strategies relating to Defendants' businesses; the development and execution of marketing, advertising, and promotion strategies by Defendants; the markets in which the Accused Products compete; the use and benefits of the Xactimate platform; the relationship and interactions between and among Defendants, EagleView, Pictometry, and EagleView Technology Corporation; the products, including those of Defendants, that compete with EagleView and/or Pictometry products; presentations, meetings, and discussions regarding EagleView, Pictometry, and/or EagleView Technology Corporation, their products, and/or the Asserted Patents; and the corporate structure of the Defendants. Mr. Fulton may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding other subject matter about which he testified at his deposition.</p>
<p>James Loveland (third party)</p> <p>1091 Hawks Rest Drive,</p>	<p>Mr. Loveland is the former President and CEO of Xactware. He may testify about his professional background; EagleView's approach to Xactware regarding a business partnership;</p>

Witness	Summary of Testimony
Mapleton, Utah 84664 c/o Mark Morris Snell & Wilmer, LLP 15 West South Temple Suite 1200 Salt Lake City, Utah 84101	Xactware's historic capabilities, including regarding the use of aerial imagery and roof modeling; development and operation of Xactimate, Aerial Sketch, and other Xactware products; the success of Xactimate; and background information on Xactware. He may also testify regarding other subject matter about which he testified at his deposition.
Peter Magnus Olson c/o McCarter & English LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102	Mr. Olson is the Senior Vice President of Data & Production at Geomni, and was formerly the Assistant Vice President of Geospatial Data Services and the Director of Imagery Services at Xactware. He may testify regarding his professional background, education, and qualifications, and about various patents, including the Asserted Patents. He may also testify regarding other subject matter about which he testified at his deposition.
Jarron Merrill c/o McCarter & English LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102	Mr. Merrill is the Assistant Vice President of Finance at Xactware. He may testify regarding his professional background; revenue and profit from the sale of the Accused Products; and related financial and accounting systems, practices, and documents. He may also testify regarding other subject matter about which he testified at his deposition.
Jeffrey Taylor c/o McCarter & English LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102	Mr. Taylor is the President of Geomni Inc. and a former Vice President of the Property InSight Group at Xactware. He may testify regarding his professional background; the operation, functionality, and use of the Accused Products and related systems; research, design, and development of the Accused Products and related systems; the Xactimate platform; historic capabilities, functions, and features of Xactimate; historical market presence of Geomni and Xactware; market reaction,

Witness	Summary of Testimony
	<p>including the reactions of end-users, to products developed, sold, and resold by Geomni and/or Xactware; Defendants' customers and customer satisfaction; the relationship and interactions between and among Defendants, EagleView, Pictometry, and EagleView Technology Corporation; presentations, meetings, and discussions regarding EagleView, Pictometry, and/or EagleView Technology Corporation, their products, and/or the Asserted Patents; the facts and circumstances underlying and supporting Defendants' positions, contentions, and arguments that Defendants do not infringe any Asserted Claim of any Asserted Patent. Mr. Taylor may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding other subject matter about which he testified at his deposition.</p>
<p>Chris Pershing (EagleView)</p> <p>c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102</p>	<p>Mr. Pershing co-founded EagleView, served as its Chief Technology Officer until 2016, and is a named inventor of the Asserted Patents. He may testify regarding his professional background; EagleView's software and the development thereof; his knowledge of the prior art; the efforts of and benefits to EagleView with respect to integration on the Xactimate platform; his purported contributions to the Asserted Patents; proceedings relevant to the Asserted Patents before the U.S. Patent and Trademark Office; public use, disclosure, or sale of the subject matter of the Asserted Patents; conception and reduction to practice of the supposed inventions of the Asserted Patents; contributions of third parties to the supposed inventions of the Asserted Patents; how Twister and Render House do not practice or embody the Asserted Patents; the level of ordinary skill</p>

Witness	Summary of Testimony
	<p>in the art relevant to the Asserted Patents; EagleView's knowledge, understanding, and use of Defendants' products; EagleView's investigation, study, and review of Defendants' products; EagleView's first awareness of Defendants' products; communications regarding any of the Accused Products, alone or in combination with EagleView's software and products; the factual basis for EagleView's allegations of infringement; facts and circumstances concerning when EagleView first formed a belief of the alleged infringement of any Asserted Claim by Defendants; the factual basis for EagleView's allegation of willful infringement; EagleView's communications with Defendants regarding the Asserted Patents; EagleView's patent marking methods; EagleView's competitors; non-infringing alternatives to products and methods claimed in the Asserted Patents; the extent of EagleView's use of Xactimate; the absence of secondary considerations of non-obviousness; the invalidity of each Asserted Claim; the factual basis for the supposed priority date of each Asserted Patent; and the disclosure of the subject matter of the Asserted Patents prior to the issuance of each. Mr. Pershing may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding other subject matter about which he testified at his deposition.</p>
<p>David Carlson (third party)</p> <p>4415 Witter Gulch Road, Evergreen, Colorado 80439</p> <p>c/o Ruttenberg IP Law</p>	<p>Mr. Carlson is named as an inventor on the '436 Patent. He may testify regarding his professional background; his knowledge of the prior art; his contribution to the purported invention(s) of the Asserted Patents; his relationship with Chris Pershing; Chris Pershing's contribution to the purported</p>

Witness	Summary of Testimony
1801 Century Park East, Suite 1920 Los Angeles, CA 90067	invention(s) of the Asserted Patents; his understanding of the Asserted Patents; his current and past relationship with EagleView and the facts and circumstances surrounding his departure from EagleView; the roofing and contracting industries; the parties to this case; and demand for EagleView products. Mr. Carlson may also testify regarding the subject matter about which he testified at his depositions.
Todd Long (EagleView) c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102	Mr. Long is Senior Manager of Report Delivery at EagleView. He may testify regarding his professional background; the operation of Render House and Twister; the division of labor at EagleView with respect to the generation of roof models and the creation of roof reports; competitors of EagleView; techniques for measuring roofs; and the content of EagleView's roof reports. Mr. Long may also testify regarding the subject matter about which he testified at his deposition.
Chris Ciarcia (EagleView) c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102	Dr. Ciarcia is a physicist at EagleView. He may testify regarding his professional and educational background; the feasibility of reverse engineering EagleView's software; sourcing of aerial imagery and information or data regarding aerial imagery; EagleView's recent development efforts regarding primitives; and Pictometry's historic capabilities to use aerial images to measure and model buildings. Dr. Ciarcia may also testify regarding the subject matter about which he testified at his deposition.
Rishi Daga (EagleView) c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza	Mr. Daga joined EagleView in 2008 and is currently its CEO. He may testify regarding his professional background; EagleView's business, business practices and methods, including the filing of lawsuits; the identity of EagleView's

Witness	Summary of Testimony
<p>1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102</p>	<p>competitors; EagleView's internal discussions about competitors and business partners, including Defendants; EagleView's sales practices; EagleView's communications to customers and potential customers of Defendants; EagleView's use of Xactimate to deliver roof reports; instances of EagleView threatening litigation or sending cease and desist letters regarding alleged infringement of intellectual property; EagleView's past and present sources of aerial imagery; EagleView's corporate structure and ownership; communications among EagleView, Pictometry, and EagleView Technology Corporation; EagleView's ownership of the Asserted Patents; Verisk's intended acquisition of EagleView and EagleView Technology Corporation; the creation of EagleView Technology Corporation; the factual basis for EagleView's claim for damages; pricing of EagleView's roof reports; computation of profits and losses from sales of EagleView's roof reports; EagleView's knowledge and understanding of other suppliers of rooftop aerial measurement products, past and present; non-infringing alternatives for the supposed inventions of the Asserted Patents; financial data relating to EagleView's products; EagleView's competitors and market share; valuation of EagleView's patents; licenses or other agreements concerning EagleView's patents; and the absence of secondary considerations of non-obvious. Mr. Daga may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding other subject matter about which he testified at his deposition.</p>

Witness	Summary of Testimony
<p>Chris Barrow (EagleView)</p> <p>c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102</p>	<p>Mr. Barrow is the former Chief Executive Officer of EagleView. He may testify regarding his professional background; EagleView's business, structure, and history, including its relationship with Defendants; the identity of EagleView's competitors; EagleView's history asserting unspecified threats of infringement against its competitors, and of filing infringement lawsuits against its competitors; EagleView's marketing practices; EagleView's roof model generation software; the value to EagleView of its business relationship with Defendants; EagleView's representations and warranties concerning intellectual property infringement to Verisk and to Vista Equity; the timing and circumstances of the filing of the present lawsuit against Defendants; and the unpatentability of the Asserted Patents. He may also testify regarding other subject matter about which he testified at his deposition.</p>
<p>Matt Quilter (EagleView)</p> <p>c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102</p>	<p>Mr. Quilter is the Chief Financial Officer of EagleView. He may testify regarding his professional background; EagleView's corporate structure, ownership, and relationships with its related entities; EagleView's merger and relationship with Pictometry; EagleView's finance and accounting systems, practices, reporting, statements, and other documentation; EagleView's finances, revenues, revenue sources, business, competition, production processes, products, sales, pricing, costs, assets, and valuations; use of Xactware's platform; and EagleView's relationship with Defendants. He may also testify regarding the subject matter of the Rule 30(b)(6) topics on which he was designated to testify, and may testify regarding</p>

Witness	Summary of Testimony
	other subject matter about which he testified at his deposition.
<p>John Keane (EagleView)</p> <p>c/o WALSH PIZZI O'REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond Blvd., Suite 600 Newark, New Jersey 07102</p>	<p>Mr. Keane is employed in the area of research and development for EagleView. He may testify regarding his professional background; his interactions with Chris Pershing and David P. Carlson; his contributions to patent inventorship on behalf of EagleView; his knowledge of EagleView's patents; his knowledge of and participation in developing roof measurement software for EagleView; the functionality of EagleView's software programs; his knowledge and understanding of EagleView's roof reports; his understanding of photogrammetry; methods for measuring roofs and generating roof reports; EagleView's business practices; his dealings with Xactware representatives; the identity of, and competition by, EagleView's competitors; EagleView's relationship with Defendants; his knowledge of the Accused Products; and the unpatentability of the Asserted Patents. He may also testify regarding other subject matter about which he testified at his deposition.</p>
<p>Adrian Alonso (Vista Equity)</p> <p>*c/o Smith Robertson, LLP 221 West 6th Street, Suite 1100, Austin, TX 78701</p>	<p>Mr. Alonso is a Senior Vice President at Vista Equity Partners. He may testify regarding his professional background; Vista Equity Partners' decision to acquire EagleView; and the representations EagleView made to Verisk and to Vista Equity regarding intellectual property infringement. He may also testify regarding other subject matter about which he testified at his deposition.</p>

Witness	Summary of Testimony
<p>Michael Allen (USAA)</p> <p>c/o Ford Murray 10001 Reunion Place, Suite 640 San Antonio, TX 78216</p>	<p>Mr. Allen is a claims service manager at USAA. He may testify regarding his professional background; USAA's use of Xactware products, use of Eagleview products, and product selection; the insurer market; and roof estimate alternatives including manual estimation. He may also testify regarding other subject matter about which he testified at his deposition.</p>
<p>Matthew Levin (MetLife)</p> <p>c/o Robinson & Cole LLP One Financial Plaza Suite 1430 Providence, RI 02903</p>	<p>Mr. Levin is a claim technical administrator at Metropolitan Property & Casualty Insurance Co (MetLife). He may testify regarding his professional background and MetLife's purchase and use of aerial roof measurement tools. He may also testify regarding other subject matter about which he testified at his deposition.</p>
<p>Jason Pawlik (The Hartford)</p> <p>c/o The Hartford Law Department One Hartford Plaza H0-1-10 Hartford, CT 06155</p>	<p>Mr. Pawlik is a Director of Claims Strategy at The Hartford. He may testify about his professional background. He may also testify about The Hartford's decision-making process in purchasing products for automobile and property claims assessments, and unpatented features of such products, such as price, format, and related customer service that factor into this decision. He may also testify regarding other subject matter about which he testified at his deposition.</p>
<p>Lynn Berard (by declaration)</p> <p>Last known contact information:</p> <p>Carnegie Mellon University Libraries, Sorrels Engineering & Science Library, 5000 Forbes Ave.,</p>	<p>As of August 24, 2016, Lynn Berard was a Principal Librarian at the Carnegie Mellon University Libraries. Ms. Berard may testify, through declaration, regarding the content of the "Declaration of Lynn Berard" executed on August 24, 2016, including her professional background, the practices and procedures of the Carnegie Mellon University Libraries, and circumstances and background information relating to the public accessibility and public</p>

Witness	Summary of Testimony
Pittsburgh, PA 15212	availability of Hsieh, Y., "Design and Evaluation of a Semi-Automated Site Modeling System," Carnegie Mellon (November 1995).
Christopher Thornberry c/o Lewis & Kappes One American Square, Suite 2500 Indianapolis, IN 46282-0003	Mr. Thornberry is a principal of Thornberry Consulting. He may testify regarding his professional background; the creation and operation of the GeoEstimator product; that the GeoEstimator product is a non-infringing alternative to the Asserted Patents; his employment with Pictometry; his separation from employment with Pictometry; his communications with EagleView and David P. Carlson; and his understanding and knowledge of Aerowest and products of this company. He may also testify regarding other subject matter about which he testified at his October 9, 2012 deposition.
Dale Thornberry c/o Lewis & Kappes One American Square, Suite 2500 Indianapolis, IN 46282-0003	Mr. Thornberry is a principal of Thornberry Consulting. He may testify regarding his professional background; the creation and operation of the GeoEstimator product; that the GeoEstimator product is a non-infringing alternative to the Asserted Patents; the identity of other competitors in the market for roof reports; his employment with Pictometry; his separation from employment with Pictometry; his communications with EagleView and David P. Carlson; EagleView's patent applications and issued patents; and his understanding and knowledge of Aerowest and products of this company. He also may testify regarding other subject matter about which he testified at his October 9, 2012 deposition.

In addition, Defendants may call any witness by deposition or live testimony identified by Plaintiff in its witness lists.

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Michael Allen (March 29, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
4:22	4:24	A, H						
6:8	6:10	A, H, In	6:5	7:1				
7:24	8:5	A, H						
11:9	11:13	A, F, H, PK, In	10:21	11:3	V, SP, IC	11:14	11:20	F, V, Spec
			11:17	11:23	IC	11:14	11:16	F, V, Spec
14:16	14:18	A, H, In	14:13	15:17	ID, Cmpd, SP, PK, V, F	41:6 42:19	41:24 43:14	F, Spec, V, H, Cmpd, Char F, Spec, H, Char, P
			17:1	17:3	ID, SP, BST	41:6 42:19	41:24 44:5	F, Spec, V, H, Cmpd, Char F, Spec, H, Char, P
17:20	19:12	A, H, P	19:21	19:24	IC, V, M, SP	20:17 20:24 21:19	20:19 21:3 21:22	F, Spec F, Spec, Arg, V F, Spec, Arg, V
19:16	19:18	A, H	19:21	19:24	IC, V, M, SP	20:17 20:24 21:19	20:19 21:3 21:22	F, Spec F, Spec, Arg, V F, Spec, Arg, V
21:19	21:24	A, F, H, Spec, C	19:21	19:24	IC, V, M, SP	20:17 20:24	20:19 21:3	F, Spec F, Spec, Arg, V
22:11	22:15	A, F, H	19:21	19:24	IC, V, M, SP	20:17 20:24 21:19	20:19 21:3 21:22	F, Spec F, Spec, Arg, V F, Spec, Arg, V
			25:4	25:24	IC, M, V, PK, SP	26:16 41:6 42:19	26:21 41:24 44:5	F, Spec, V F, Spec, V, H, Cmpd, Char F, Spec, H, Char, P

Michael Allen (March 29, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
23:21	24:5	A, F, H	24:9	25:2	IC, PK, SP, V, F, NE	26:16 41:6 42:19	26:21 41:24 44:5	F, Spec, V F, Spec, V, H, Cmpd, Char F, Spec, H, Char, P
			25:4	25:24	IC, M, V, PK, SP	26:16 41:6 42:19	26:21 41:24 44:5	F, Spec, V F, Spec, V, H, Cmpd, Char F, Spec, H, Char, P
41:6	41:24	A, F, H, P	40:20	40:23	IC, LD, F, V, SP, PK	40:7 40:13 40:18	40:11 40:16 40:19	F, Spec, V F, Spec, H F, Spec, V, Arg
			42:4	42:13	IC	42:19	44:5	F, Spec, H, Char, P
42:19	43:14	A, F, H	44:11	44:14				
43:23	44:5	A, F, H, C	44:11	44:14				
44:11	44:14	A, F, H						
53:25	54:2	A, F, H, PK	53:10	53:12	IC, LD, V, NE	52:17 53:1	52:18 53:9	F, V, Spec F, V, Spec
54:13	54:17	A, F, H, PK	57:16	57:23	IC, PK, D, A, SP, V, LD, H, SP	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			58:4	58:9	IC, D, A, SP, PK, V, LD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			58:14	58:16	IC, PK, D, A, SP, V, LD, H	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			58:20	59:9	IC, PK, D, A, SP, V, LD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			59:12	59:17	IC, D, A, SP, V, LD, H, PK	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			59:19	59:23	IC, D, A, SP, V, LD, H, PK, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			60:1	60:4	IC, PK, D, A, SP, V,	57:6	57:10	F, V, Spec

Michael Allen (March 29, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
					LD, MD	57:24	58:2	F, V, Spec
			60:8	60:9	IC, PK, A, SP, V, LD, D, MD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			60:12	61:7	IC, PK, D, A, SP, V, LD, MD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			61:11	61:20	IC, PK, D, A, SP, V, LD, MD, At	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			61:23	61:25	IC, PK, D, A, SP, V, LD, MD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			62:3	62:6	IC, PK, D, A, SP, V, LD, MD, Cmpd	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			62:9	62:20	IC, PK, D, A, SP, V, LD, MD, Cmpd	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			63:7	63:10	PK, V, LD, M	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
54:19	55:12	A, F, H, PK, P, AT: 54:23	57:16	57:23	IC, PK, D, A, SP, V, LD, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			58:4	58:9	IC, D, A, SP, PK, V, LD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			58:14	58:16	IC, PK, D, A, SP, V, LD, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			58:20	59:9	IC, PK, D, A, SP, V, LD, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			59:12	59:17	IC, D, A, SP, V, LD, H, PK, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			59:19	59:23	IC, D, A, SP, V, LD, H, PK, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			60:1	60:4	IC, PK, D, A, SP, V, LD, MD, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec

Michael Allen (March 29, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			60:8	60:9	IC, PK, A, SP, V, LD, D, MD, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			60:12	61:7	IC, PK, D, A, SP, V, LD, MD, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			61:11	61:20	IC, PK, D, A, SP, V, LD, MD, 1002, AT	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			61:23	61:25	IC, PK, D, A, SP, V, LD, MD	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			62:3	62:6	IC, PK, D, A, SP, V, LD, MD, Cmpd, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			62:9	62:20	IC, PK, D, A, SP, V, LD, MD, Cmpd, H, 1002	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec
			63:7	63:10	PK, V, LD, M	57:6 57:24	57:10 58:2	F, V, Spec F, V, Spec

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Adrian R. Alonso (January 30, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
10:20	10:24	Personal (Address), R, P, ML						
11:14	11:21	R, P, ML						
16:20	17:5	R, P, ML						
17:10	17:14	R, P, ML						
21:5	21:11	R, P, ML						
22:19	23:9	R, P, ML	23:10	23:18	R			
32:25	33:16	R, P, ML						
34:14	36:20	R, P, ML, F, Spec, H	38:6	38:18	R, PK, NR			
			38:19	39:7	R, PK, NR			
41:1	42:15	R, P, ML, F, Spec, H	40:1	40:6				
			40:12	40:25	R, PK,C			
46:20	46:24	R, P, ML, 30(b)(6), F						
47:2	47:3	R, P, ML, 30(b)(6),						

Adrian R. Alonso (January 30, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
		F						
47:5	47:14	R, P, ML, 30(b)(6), F						
47:16	50:7	R, P, ML, F:46:16-17-30(b)(6)						
59:24	60:15	R, P, ML	60:16	61:2	R, PK			
			61:25	62:25	R, PK, NR			
61:3	61:24	R, P, ML	61:25	62:25	R, PK, NR			
			60:16	61:2	R, PK			
63:13	63:20	R, P, ML						
64:21	68:11	R, P, ML						
83:11	84:13	R, P, ML	84:14	85:11	R, NR, C			
			88:10	90:19	R, C, H, P, LC, PK			
87:15	87:24	R, P, ML	88:10	90:19	R, C, H, P, LC, PK			
88:1	88:8	R, P, ML	88:10	89:15	R, C, H, P, LC, PK			
109:13	110:2	R, P, ML, F, H	115:9	116:8	PK, H			
113:17	115:8	R, P, ML, F, H	115:9	116:8	PK, H			
116:9	116:22	R, P, ML, F, H						

Adrian R. Alonso (January 30, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
117:7	117:17	R, P, ML, IN	117:18	117:23				
118:17	119:6	R, P, ML						
119:14	119:23	R, P, ML, Spec, C, H, F, PK	120:8	120:17	F			
121:1	121:15	R, P, ML, Spec, PK, C, H, F	123:23	124:6				
123:4	123:22	Spec, R, P, PK, C, H, F, ML	123:23	124:6				
127:20	129:23	Spec, R, P, PK, C, H, F, ML	132:20	134:14	F			
132:12	132:19	Spec, R, P, PK, C, H, F, ML	132:20	134:14	LC, IO, 701			
136:19	138:12	R, P, ML, Arg., C						
138:13	138:25	R, P, ML, F						
145:1	145:13	R, P, ML						
145:22	145:25	Spec, R, P, PK, H, L, ML						
155:17	156:6	Spec, R, P, PK, ML	156:19	157:8	PK, R			
156:10	156:18	Spec, R, P, PK, H, F, ML	156:19	157:8	PK, R			

Adrian R. Alonso (January 30, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
157:9	158:16	Spec, R, P, PK, H, F, ML	156:19	157:8	PK, R			
158:25	159:16	Spec, R, P, PK, H, F, ML	156:19	157:8	PK, R			
159:18	160:14	Spec, R, P, PK, H, F, ML	156:19	157:8	PK, R			
160:16	161:2	Spec, R, P, PK, H, F, ML	161:3	161:6	PK	161:12 161:15	161:13 161:15	NR, M, C, R
			161:8	161:10		161:12 161:15	161:13 161:15	NR, M, C, R
			161:17	162:12		162:13	162:17	H, R, C,
162:22	163:12	Spec, R, P, PK, H, F, ML						
166:21	167:12	Spec, R, P, PK, ML						
167:14	167:14	Spec, R, P, PK, ML						
173:17	174:5	Spec, R, P, PK, F, ML						
174:8	174:11	Spec, R, P, PK, F, ML	174:13	175:1	PK, NT			
175:2	175:6	Spec, R, P, PK, F, ML						

Adrian R. Alonso (January 30, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
177:18	178:13	Spec, R, P, PK, H, ML	177:10	177:17	PK	177:2	177:9	H, PK, F, R
178:16	178:17	Spec, R, P, PK, H, ML						
183:9	183:15	R, C, PK, Spec, P, ML						
183:21	184:3	R, C, PK, Spec, ML						
186:9	187:13	Spec, R, P, PK, H, ML						
189:18	191:13	Spec, R, P, PK, H, ML						
192:6	194:16	Spec, R, P, PK, H, ML						
194:19	194:20	Spec, R, P, PK, H, ML						

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
11:13	11:19		7:9	7:14				
12:13	13:2							
15:9	15:21	P, R	15:22	16:1				
16:2	17:5	P, R, C						
17:7	17:9	P, R, C						
17:11	17:14							
18:6	18:10	P, R, C						
18:16	18:22		18:23	19:2	R, V, P			
19:10	19:14	P, R, C, spec						
19:16	19:25	P, R, C, spec						
20:23	21:6	R	21:7	21:15	R	21:16	21:18	R
21:19	22:4	R, spec, M						
24:14	24:15	R, PK, P, spec	24:1	24:13	R, NR, BSE			
24:17	25:13	R, PK, P, spec						
25:23	27:6	P, R, C, spec						
27:22	27:24		27:7	27:12	R, NR, V, M, P, C			

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
30:21	31:22	P, R, C, spec						
32:15	33:17	P, PK, R, C, spec						
33:19	33:21	P, PK, R, C, spec						
33:23	34:2	P, PK, R, C, spec						
34:7	35:10							
36:20	38:6	R, P						
38:13	39:6	R, P						
39:8	39:13	R, P						
44:14	46:21	R, P, C						
47:7	47:24	R, P, C						
49:4	51:6	R, P, C						
51:17	52:7	R, P, C						
52:16	54:4	R, P, C, H, PK						
56:9	56:23	R, P, PK, M, In	56:24	57:15	SP, H, P, PK			
58:17	58:19	R, P, PK, M, In						
58:23	58:23	R, P, C, H						
59:14	62:9	R, P, C						
62:25	63:6	R, P, C, H	62:10; 62:15	62:13; 62:24	IC R, NR			

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
64:1	67:23	R, P, C, H						
68:19	69:3	C	69:4; 69:8	69:5; 70:14	IC H, SP, P			
70:19	71:9	H, R, P, C						
71:24	72:10	H, R, P, C						
72:12	72:16	H, R, P, C, M						
74:9	75:3	H, R, P, C, M	73:12	73:21	PK, SP, V, R			
75:11	75:18	H, R, C						
77:6	77:24	H, C						
78:10	78:18	H, C						
78:25	79:23	H, C	79:7	79:23				
80:11	81:8	H, C						
81:18	82:5	H, R, P, C, M						
84:11	85:19	H, R, C, P						
89:7	89:9	R, C						
91:14	91:22	R, C						
92:17	92:23	R, C						
93:1	93:13	R, C						
94:16	94:18		94:19	94:21	SP, PK			

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
94:25	96:3	C						
96:13	96:16	C						
96:18	97:14	C						
98:2	98:5							
98:10	98:12	P, M, In	98:13	99:10	NR, V, PK, SP			
101:3	101:10							
102:1	103:13	R, C, P						
103:21	103:25	R, C, P						
105:16	107:2	R, C						
115:11	117:17	R, C, P						
117:19	118:20	R, C, P, Spec, PK, M						
118:22	119:1	R, C, P, Spec, PK, M						
119:9	119:13	R, C, P						
121:1	121:25	R, C, P, H						
126:25	127:4	R						
128:20	128:23	R, C, P						
128:25	129:6	R, C, P						

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
129:18	130:13	R, C, P						
131:18	132:10	R, C, P, H	132:11	132:23	NR, V, R			
132:24	132:25	R, C, P	133:1	133:2	C			
133:3	135:9	R, C, P, H, Spec, PK, F, M						
135:12	135:17	R, C, P, H, Spec, PK, F, M						
139:3	139:9	R, C, P, H, Spec, PK, F, M	139:13	139:15	R, NR, C			
139:16	139:20	R, C, P, H, Spec, PK, F, M						
139:22	139:23	R, C, P, H, Spec, PK, F, M						
140:3	142:3	R, C, P, H, Spec, PK, F, M						
142:22	143:15	R, C, P, H, Spec, PK, F, M	143:16	144:1	NR, C			
144:20	145:22	R, C, P, H, Spec, PK, F, M						
149:15	150:16	R, C, P, H						
151:5	153:20	R, C, P, H, Spec, PK, F, M	153:21	153:25				

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
160:3	160:9							
160:15	160:23							
161:11	161:12	C, R						
161:14	161:19	C, R						
166:10	166:13	C, R, P, M, In	166:14; 166:20	166:15; 166:23	IC NR, P, R, BSE			
167:22	168:7	H, C, P, R						
168:9	168:9	H, C, P, R						
168:14	169:13	H, C, P, R						
170:5	170:24	H, C, P, R, PK						
171:21	171:24	C, R						
172:20	173:18	C, R, H, PK	173:19	174:1	SP, PK			
177:14	177:24	H, C, P, R, PK	177:25	179:8	NR, R, SP, PK, BSE			
179:9	179:15	H, C, P, R, PK, In	179:16	180:6	NR, R			
180:7	180:11	H, C, P, R, PK						
182:13	183:6	H, C, P, R						
186:25	187:6	C, P, R						
188:2	188:21	C, P, R						
191:10	191:12	C, P, R						

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
191:15	191:22	C, P, R						
191:24	192:4	C, P, R						
192:18	193:4	C, P, R, In	193:12	195:1	H, NR, PK, SP	195:2 195:5	195:3 195:20	IC, NR, C
198:23	200:5	H, C, P, R						
203:4	204:1	C, In	204:2	204:13				
204:14	205:16	In						
206:21	207:18	In						
212:2	212:12	In						
212:22	215:3	H, R, P, C, PK						
216:7	216:25	H, R, P, C, PK						
217:7	220:25	H, R, P, C, PK, In	217:1	217:3				
221:4	221:18	H, R, C						
222:25	223:2	H, R, C						
223:23	224:19	H, R, C						
224:25	226:19	H, R, C						
227:16	227:23	R, C, PK, Spec						
228:2	228:15	R, C, PK, Spec						
234:11	235:4	H, R, C						

Chris Barrow (November 9, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
235:21	235:24	H, R						
236:9	236:12	R						
236:19	236:22	R, P, PK, Spec						
240:8	240:18	H, PK, F, R, P						
242:24	244:3	H, PK, F, R, P						
245:9	245:20	H, R, P, C						
247:20	247:25	H, R, P, C	248:1	248:11	H, SP			
250:22	252:9	H, R, P, C	250:17	250:21				
252:11	252:13	H, R, P, C						
254:21	256:17	H, R, P, C						
259:2	260:1	H, R, P, C						
262:1	262:18	H, R, P, C						
262:20	263:14	H, R, P, C						

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Christopher Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
4:10	4:13							
5:12	6:9	V, C						
6:16	7:2	F, V						
7:8	7:16							
8:10	8:18	V	8:23	8:25	V, NR			
9:1	9:10							
9:16	9:19	V						
9:24	10:8	V						
10:11	10:11							
11:17	11:24	R, P, C						
12:8	12: 11		12:12	12:14	R, V			
			12:18	12:19	R, V			
12:20	12:22		12:23	13:5	R, V			
13:6	13:24	R, P						
14:16	15:12	R, P						

Christopher Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
16:10	18:6	R, P, H, F, PK, Spec,	20:2	20:4	R, H			
			20:7	20:9	R, PK			
			20:12	20:12	R, PK			
21:1	21:5	R, P, H, F						
21:8	21:10	R, P						
21:13	21:13	R, P						
22:4	22:7	R, P, H, F						
22:16	22:20	R, P, H, F, PK, Spec						
23:1	23:21	R, P, H						
24:2	24:5	R, P, H, MD	24:9	24:12	V, PK, SP			
			27:10	27:20	V, PK			
24:20	25:1	R, P, H						
25:13	25:19	R, P, V						
26:2	26:8	R, P, H, F, PK, Spec, LC, 701	39:16	39:18	SP, PK, V, P			
			39:21	39:21	SP, PK, V, P			
26:18	26:21	R, P, M						
29:8	29:11	R, P	29:12	29:13	ID, R	30:22	30:25	R, P, C, M

Christopher Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			48:1	48:4	ID, R	30:22	30:25	R, P, C, M
32:22	33:19	R, P, F						
42:2	42:3	R, P						
42:14	42:22	R, P, H						
50:5	50:8	R, P						
50:18	50:22	R, P, H, F, PK	50:23	51:2	R, SP, PK, Cmpd, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			52:5	52:7	R, SP, PK, V, ID	53:25 54:8	54:4 54:8	
			55:13	55:15	R, SP, PK, Cmpd, ID	53:25 54:8	54:4 54:8	
			55:19	55:24	R, SP, PK, Cmpd, ID	53:25 54:8	54:4 54:8	
			56:7	56:8	R, SP, PK, ID	53:25 54:8	54:4 54:8	
			56:11	56:11	R, SP, Cmpd, ID	53:25 54:8	54:4 54:8	
			57:7	57:13	R, SP, PK, Cmpd, ID, V	53:25 54:8	54:4 54:8	

Christopher Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			57:17	57:25	R, SP, PK, ID, V	53:25 54:8	54:4 54:8	
51:18	51:20	R, P, H	50:23	51:2	R, SP, PK, Cmpd, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			52:5	52:7	R, SP, PK, V, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			55:13	55:15	R, SP, PK, Cmpd, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			55:19	55:24	R, SP, PK, Cmpd, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			56:7	56:8	R, SP, PK, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			56:11	56:11	R, SP, Cmpd, ID	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			57:7	57:13	R, SP, PK, Cmpd, ID, V	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
			57:17	57:25	R, SP, PK, ID, V	53:25 54:8	54:4 54:8	R, P, C, F, PK, Spec
53:25	54:4	R, P, H, C						
54:20	54:24	R, P, F, PK, LC, 701, Spec, C						
55:2	55:7	R, P, F, PK, LC,						

Christopher Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
		701, Spec, C						
55:12	55:12	R, P, F, PK, LC, 701, Spec, C						
58:19	58:22	R, P, V						
58:24	58:24	R, P						

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

David Carlson (September 28, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
6:19	6:22		20:20; 21:5; 21:12; 23:2; 23:18	21:2; 21:7; 22:9; 23:8; 23:22	R, BSE (for all)			
24:4	25:17	R	25:18; 183:9	26:9; 184:4	R, BSE (for all)			
26:10	26:20		25:18	26:9	R			
27:10	28:4	H, F, PK, Spec, 701, M, V						
28:6	28:6	H, F, PK, Spec, 701, V						
28:11	28:17	H, F, PK, Spec, NE, M						
34:16	37:1	H	30:12; 31:4; 32:1; 32:14; 37:2	30:24; 31:23; 32:6; 34:15; 37:3	BSE (for all) F, R, H, NT (for 32:14-34:15)			

David Carlson (September 28, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
37:13	37:22	H, P, M						
38:19	40:2	H, P, M						
40:8	41:6	P, PK, Spec, M	41:22	42:20	F, H, NR			
44:22	44:24		44:25	45:3	BSE, SP, PK			
45:4	45:25	R, IC	46:1; 48:15	48:13; 49:19	R			
66:21	66:23	R, P	72:5; 86:16; 163:14; 164:2; 184:6	72:20; 87:11; 163:23; 164:25; 184:11	BSE (for all) R (72:5-72:20) SP (for 164:2-25) ID (for 184:6-11)	165:1 165:6 165:10 166:9	165:2 165:8 166:5 166:9 (all for for 163:14- 163:23, 164:2- 164:25)	R, P, F, PK, Spec
88:5	88:20	R, P, PK, Spec, NE	88:21; 88:24	88:22; 89:5	R, SP, H, BSE (for all)			
93:11	93:23	PK, Spec	89:16; 90:20	89:24; 91:19	H, SP, BSE (for all)			
95:2	95:6	R, IC, PK, Spec, NE, M						
97:16	98:6							

David Carlson (September 28, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
101:4	101:11	PK, Spec, 701, LC, V						
101:17	101:19	PK, Spec, 701, LC						
101:23	101:25	PK, Spec, V						
102:9	103:16	PK, Spec, 701, LC, V	105:22; 106:7; 106:24; 108:7; 108:13; 110:23	106:4; 106:22; 107:6; 108:10; 109:3; 111:22	SP (105-106) F, BSE, (107-109, 110-111) R, BSE (110-111)	107:7 (for 106:24-107:6) 109:10	108:6 110:21 (for 108:13-109:3, 110:23-111:22)	C, F, PK, Spec, 702, LC, IC, ML
103:19	105:10	PK, Spec, 701, LC, V	105:22; 106:7; 106:24; 108:7; 108:13; 110:23	106:4; 106:22; 107:6; 108:10; 109:3; 111:22	SP (105-106) F, BSE, (107-109, 110-111) R, BSE (110-111)	107:7 (for 106:24-107:6) 109:10	108:6 110:21 (for 108:13-109:3, 110:23-111:22)	C, F, PK, Spec, 702, LC, IC, ML
116:15	116:19	R, PK	117:1;	117:13;	SP, PK, BSE, R (for	118:4	119:3 (for 117:1-13,	C, F

David Carlson (September 28, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			117:16; 119:4; 119:14; 119:22	117:18; 119:10; 119:20; 120:8	all)		117:16-18)	
120:12	120:16	M, V, 701, LC						
121:11	122:2	PK, Spec, 701, LC, V						
126:7	127:20	PK, Spec, 701, NE, V	128:20; 130:1	128:23; 131:4	BSE, F, V (for all) Also add ID, H, SP, PK for 130:1-131:4	128:24	129:25	R, C, F, PK, Spec
136:6	136:19	V	135:13; 135:18	135:16; 135:25	BSE, SP, PK (for all)			
161:20	161:21	V, ML	163:2	163:10	ID, SP, V, NR			
161:23	162:5	V, ML	163:2	163:10	ID, SP, V, NR			
162:18	162:21	V, ML, C	163:2	163:10	ID, SP, V, NR			
178:22	179:25	R, P, NE, V	177:20; 178:2	177:23; 178:12	SP, PK, BSE (for all)			
180:17	181:2	R, PK						
181:4	181:4	R, PK						

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

David Carlson (March 26, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
234: 10	235:1	R, P, PK, F						
274:22	275:3	P, Arg, C	277:19	278:1	F, SP, C			
275:12	275:25	H, P, C	277:19	278:1	F, SP, C			
302:7	302:19	F, H, P, C, AT, V	290:8 290:20 292:11 292:24 293:13 296:3 298:18 300:5 302:20 306:9	290:11 290:23 292:15 293:10 294:6 296:18 298:25 300:16 303:1 307:19	BSE (for all) F (292:11-15, 292:24-293:10, 293:13-294:6, 06:9- 307:19) SP (300:5-16, 306:9-307:19) V (300:5-16, 306:9- 307:19) NR (292:11-15, 292:24-293:10, 296:3-296:18; 298:18-298:25,			

David Carlson (March 26, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
					306:9-307:19) ID (296:3-296:18)			
334:12	334:17	C						
334:21	335:1	C, F	312:22	312:25				
345:13	345:18	C, F, V, LC	346:17 347:7	346:20 347:7	ID , V, SP (all for 347:7)	347:2	347:4 (for 347:7)	

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Christopher A. Ciarcia (December 14, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
7:22	7:25							
10:15	12:6		18:14	19:4				R, PK, Spec
			23:22	23:24				
			52:7	52:14		52:15	53:4	
			53:8	54:14				
84:24	85:23	R, Spec, V, IC	84:8 84:22 91:3 159:5	84:15 84:23 91:14 159:19				
85:25	86:4	R, Spec, V	159:5	159:19				
86:6	86:10	NR	86:20	86:25				
			87:3	87:22	NR			
			146:22	146:24				
			147:1	148:11	R			
			148:19	149:5	SP			
			161:11	162:20	SP; PK, F	162:21 163:2	162:24 163:11	F, MD, PK, Spec, LC, 702

Christopher A. Ciarcia (December 14, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						163:13	164:17	R, C
			164:18	164:19	SP; PK	162:21 163:2 163:13	162:24 163:11 164:17	F, MD, PK, Spec, LC, 702 R, C
			164:21	165:1	SP; PK; H	162:21 163:2 163:13	162:24 163:11 164:17	F, MD, PK, Spec, LC, 702 R, C
90:2	90:21	R, F, PK, Spec, C, IC	159:5	159:19				
112:25	113:4	F, PK, Spec	112:14	112:24				
113:6	113:24	F, PK, Spec, NR						
125:15	126:17	R, P	125:12 126:21 127:1 127:25 128:9 128:13 128:23	125:14 126:23 127:4 128:7 128:11 128:20 128:24				
129:1	129:8	R, P, PK, V						
129:10	129:12	R, P, PK, V						
129:14	129:16	R, P, PK, V						

Christopher A. Ciarcia (December 14, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
136:4	136:6	R, P, F, PK, Spec	135:20 138:3 138:13 138:16	135:21 138:10 138:14 138:19				
136:8	137:19	R, P, F, PK, Spec	135:20	135:21	ID	135:16	135:18	R, C, IC
			138:3	138:10	F, ID	137:22	138:2	R, C
			138:13	138:14	ID	138:15	138:15	
			138:16	138:19				
			141:9	141:10				
			141:13	141:16	NR			
			141:18	141:20				
			141:22	143:4				
			143:7	144:9	SP	145:14 145:19	145:16 145:22	M, F, Spec, 702, LC

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Dale Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
4:10	4:12							
6:12	6:22							
7:1	7:14	R, P, V	7:15	7:17	R, V			
7:18	8:3	R, P	7:15	7:17	R, V			
8:20	9:1							
10:1	10:5	F, NE, V						
10:12	10:16	C, PK, Spec	10:24	11:11	SP, PK, V			
11:25	13:22	H, V, PK, Spec	10:24	11:11	SP, PK, V			
			25:12	26:5	SP, PK, V, F			
			26:9	26:15	SP, PK, V, F			
14:2	14:7							
14:24	15:2	R, P						
15:13	15:15	V						
15:19	15:21	V						
16:5	16:10	R, P, V	16:11	16:13	R			
16:14	16:16		16:17	16:19	R, V			

Dale Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
16:25	18:13	F, PK, Spec, V	18:14	18:16	V			
18:17	18:24	R, P	18:14	18:16	V			
22:8	24:1	F, R, P, PK, Spec, V						
24:7	25:6	R, P						
26:6	26:8							
26:16	27:10	R, P	26:9	26:15	R, SP, PK, V, F			
			27:11	27:19	SP, V, F, R, P			
28:10	28:17							
29:7	30:9	R, P, H, F, PK, Spec, LC, 701, V	86:8	86:9	R, V, ID	84:22 85:13 85:24	85:11 85:14 86:7	R, P, C
			86:13	86:19	R, V, ID	84:22 85:13 85:24	85:11 85:14 86:7	R, P, C
30:24	31:15	IC						
32:8	32:25	R, P						
33:5	33:18	R, P, C, F, PK, Spec, M						
35:10	36:6	R, P, H, NR	36:7	37:3	R, V, H,			
			39:6	39:8	R, V, ID, BSE	39:2	39:5	R, P, C

Dale Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						39:9	39:12	
			39:13	39:17	R, V, ID, BSE	39:2 39:9	39:5 39:12	R, P, C
			68:8	68:14	R, V, H, SP			
			68:16	68:21	R, V, SP, PK, AT			
			68:25	69:5	R, V, SP, PK,			
			68:8;	68:10	R, V, SP, ID, F, IO			
			68:13	68:13	R, V, SP, ID, F, IO			
37:4	37:6	R, P, H						
37:15	37:16	R, P, H	37:17	37:18	ID, R, PK	37:19	37:20	R, P, C, PK, Spec
			37:21	37:22	ID, R	37:19	37:20	R, P, C, PK, Spec
37:23	39:1	R, P, H, M, F, PK, Spec, LC, 701, V	37:17	37:18	ID, R, PK	37:19	37:20	R, P, C, PK, Spec
			37:21	37:22	ID, R	37:19	37:20	R, P, C, PK, Spec
39:21	40:3	R, P	66:11	66:20	ID, R	40:4 65:7 66:4 66:21 67:11 67:17 67:21	40:12 67:20 66:10 66:25 67:15 67:19 67:21	R, P, C, V, F, PK, Spec, AT

Dale Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			67:6	67:10	ID, R	40:4 65:7 66:4 66:21 67:11 67:17 67:21	40:12 67:20 66:10 66:25 67:15 67:19 67:21	R, P, C, V, F, PK, Spec, AT
40:18	41:2	R, P, H	65:21	66:3	ID ,SP, PK, LD	40:4 65:7 66:4 66:21 67:11 67:17 67:21	40:12 67:20 66:10 66:25 67:15 67:19 67:21	R, P, C, V, F, PK, Spec, AT
42:14	42:25	R, P, H, F, M, MD						
44:10	45:6	R, P, H, V, M, MD, F, PK, Spec, IC	45:7	45:13				
45:14	45:17	R, P, H						
45:23	47:2	R, P, H, F, PK, Spec, M, MD	70:14	70:15	R, ID	69:20 70:9	70:6 70:13	R, P, C
			70:17;	70:17;	R, ID	69:20 70:9	70:6 70:13	R, P, C
			70:19;	70:21;	R, ID, SP, PK	69:20 70:9	70:6 70:13	R, P, C

Dale Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			70:23;	71:1;		69:20 70:9	70:6 70:13	
			71:3;	71:3;		69:20 70:9	70:6 70:13	
			71:9	71:14		69:20 70:9	70:6 70:13	
47:6	47:8	R, P, F, PK, Spec, M, MD						
49:16	50:14	R, P, H, F, LC, 701, V, MD	49:4	49:15	H, SP, ID	48:13 50:19 51:3	49:3 50:22 51:7	R, P, C, H, F, PK, Spec, LC, 701, V, MD, M
50:19	50:22	R, P, H, F, PK, Spec, IC	84:6	84:21	H, SP, PK	50:19 51:3	50:22 51:7	R, P, C, H, F, PK, Spec, LC, 701, V
51:4	51:19	R, P, H, F, PK, Spec, LC, 701, V, MD			H, SP, PK			
52:9	52:15	R, P, H, MD, M, F, LC, 701,	52:4	52:8	ID			
52:19	53:8	C, R, P, H, M						
54:12	54:16	R, P, H						
54:24	55:4	R, P, H						
56:25	57:9	R, P, H, F, PK, LC,						

Dale Thornberry (October 9, 2012)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
		Spec, 701, MD						
58:17	58:24	R, P						
59:5	59:8	R, P						
63:19	64:21	R, P, PK, Spec						
69:14	69:16	R, P, V						
69:19	69:19	R, P, V						
72:8	72:16	R, P	72:17	72:18	ID, V, Cmpd, NT			
72:20	72:21	R, P						
72:23	73:2	R, P						
88:24	89:4		89:5	89:8	ID, SP,	49:16	50:14	R, P, H, F, LC, 701, V, MD

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
7:1	7:8	Personal (address)						
7:23	8:9							
11:2	12:4							
14:6	14:10	R						
14:17	15:4	R, P, ML, Char						
16:4	16:16	R, P, ML, Char						
17:9	17:14	R						
17:23	18:6	R, P, ML						
19:6	20:7	R, P, ML (19:6-10, 19:21-23)	20:9	20:13				
21:6	21:9	R, P						
21:23	22:2	ML						
22:8	22:18	ML, F						
22:22	22:24							
23:4	23:6	ML						
23:9	25:5	R, P (24:5-16)						

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
27:22	27:24		27:25	28:1	R			
28:11	29:7							
29:14	29:25							
30:16	30:24	In	30:25	30:25				
31:1	32:7	In	30:25	30:25				
34:6	34:20							
40:3	40:21							
44:14	45:11							
46:15	46:19							
47:1	47:4							
49:1	49:4							
51:7	51:16							
52:3	52:24	30(b)(6), R, P	55:14;	55:20;	R; C			
			56:2;	56:14	R; C			
			56:8	56:6;	R; C			
53:1	54:23	30(b)(6), R, P, Spec, PK	55:14;	55:20;	R; C			
			56:2;	56:6;	R; C			
			56:8	56:14	R; C			

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
54:25	54:25	30(b)(6)	55:14;	55:20;	R; C			
			56:2;	56:6;	R; C			
			56:8	56:14	R; C			
55:2	55:4	30(b)(6)	55:14;	55:20;	R; C			
			56:2;	56:6;	R; C			
			56:8	56:14	R; C			
57:23	58:11							
59:6	59:8		59:9	59:10				
59:20	60:22		60:23	60:25				
62:4	62:11		62:12;	62:16;				
			62:18	62:21				
62:22	63:3		62:12;	62:16;				
			62:18	62:21				
65:11	66:10	30(b)(6) (66:7-10)	66:16;	66:16;	SP; PK; IC	68:5	68:11	PK, Spec, R, P, V
			66:18;	66:18;	SP; PK; IC	68:5	68:11	PK, Spec, R, P, V
			68:12	69:21	R; NR; C; IC	68:5	68:11	PK, Spec, R, P, V
66:12	66:12	30(b)(6)	66:16;	66:16;	SP; PK; IC	68:5	68:11	PK, Spec, R, P, V
			66:18;	66:18;	SP; PK; IC	68:5	68:11	PK, Spec, R, P, V

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			68:12	69:21	R; NR; C; IC	68:5	68:11	PK, Spec, R, P, V
66:14	66:14	30(b)(6)	66:16;	66:16;	SP; PK; IC	68:5	68:11	PK, Spec, R, P, V
			66:18;	66:18;	SP; PK; IC	68:5	68:11	PK, Spec, R, P, V
			68:12	69:21	R; NR; C; IC	68:5	68:11	PK, Spec, R, P, V
66:19	66:22		68:12	69:21	NR; C; IC	68:5	68:11	PK, Spec, R, P, V
66:25	66:25		68:12	69:21	NR; C; IC	68:5	68:11	PK, Spec, R, P, V
69:23	70:9		70:10	70:21				
70:22	71:12		70:10	70:21				
72:8	73:14							
73:22	74:11							
75:24	76:7							
76:9	76:13		76:22	82:7	R; NR; C; P; IC	76:14	76:21	
82:8	82:21		76:22	82:7	R; NR; C; P; IC	76:14	76:21	
89:14	90:14							
90:20	91:6		91:7;	92:5;	R; C; NR			
			92:13;	92:22;	R; C; NR			
			93:22;	93:25;	R; C			
			94:2	94:13	R; C; NR			

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
92:6	92:12		91:7;	92:5;	R; C; NR			
			92:13;	92:22;	R; C; NR			
			93:22;	93:25;	R; C			
			94:2	94:13	R; C; NR			
92:23	93:8		91:7;	92:5;	R; C; NR			
			92:13;	92:22;	R; C; NR			
			93:22;	93:25;	R; C			
			94:2	94:13	R; C; NR			
93:10	93:21		91:7;	92:5;	R; C; NR			
			92:13;	92:22;	R; C; NR			
			93:22;	93:25;	R; C			
			94:2	94:13	R; C; NR			
94:14	94:21		91:7;	92:5;	R; C; NR			
			92:13;	92:22;	R; C; NR			
			93:22;	93:25;	R; C			
			94:2	94:13	R; C; NR			
99:10	100:20	AT (99:21), R, P (99:20, 99:22- 100:20)						

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
100:22	100:23	R, P						
104:7	104:16	In, R, P	94:22;	95:5;		95:6	95:13	
			101:21;	102:9;		102:10	103:11	C, R, P
			103:18	103:21		103:23	104:1	C, R, P, 30(b)(6)
105:2	105:12		105:13	105:18				
109:14	109:19		108:21	109:5	NT; H; 1002; IC	109:6	109:8	C, R, P, 30(b)(6)
109:22	110:1	AT						
113:13	113:18	In	113:19;	113:20;				
			113:22	113:25	NR			
114:1	114:2	In	114:7	114:13				
114:4	114:6		114:7	114:13				
114:14	115:4	AT (115:1), 30(b)(6), F (114:25, 115:2-3, 115:4)	114:7	114:13				
115:6	115:15	30(b)(6), F (115:6-7)						
115:17	115:22							

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
115:24	116:6							
117:10	118:8							
118:16	119:12							
120:20	121:11							
121:20	121:23							
123:1	123:21		122:18	122:25	NT			
124:25	125:15		123:25	124:3	R			
126:7	126:18		126:19	126:19				
133:18	134:7							
137:11	137:19							
138:19	139:2							
139:10	139:20		139:6	139:9	NT			
140:5	140:9							
141:18	142:9	In (142:1-7), 30(b)(6) (142:8-9)						
142:12	142:19	30(b)(6) (142:12-14, 142:15-19)						
142:22	143:1	30(b)(6) (142:22)						
143:3	143:7							

Matthew Quilter (October 18, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
143:9	144:14	AT (144:9)	144:15;	144:20;				
			144:22	145:1	NR			
146:18	147:4							
151:15	151:20	R, P, PK						
156:9	156:12	R, P, F	156:3;	156:4;				
			156:6	156:8				
156:15	156:15	R, P, F						
160:10	160:22	R, P, F						
161:1	161:7	R, P, C						

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
6:15	6:22							
7:4	7:10							
8:7	8:9		8:10 15:18	8:20 16:17	R, NR, BSE R, NR, BSE			
8:21	9:19							
9:24	10:4	R	13:14 14:4	14:1 14:7	R, V R, V			
11:18	11:22	R	13:14 14:4	14:1 14:7	R, V R, V			
11:24	12:2	R	13:14 14:4	14:1 14:7	R, V R, V			
14:16	14:23	R, V	13:14 14:4	14:1 14:7	R, V, NR, BSE R, V, NR, BSE			
18:6	18:7	F, V	18:8	18:10	R			
18:11	18:14	F, V	18:8	18:10	R			
18:25	19:5		18:8	18:10	R			
19:13	19:16	V						

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
19:17	19:17	IC	19:18 20:1	19:23 20:2				
20:3	20:4		19:18 20:1	19:23 20:2	R, NR, V R, NR, V			
20:10	20:19	V	19:18 20:1	19:23 20:2	R, NR, V, BSE R, NR, V, BSE			
20:22	21:2	V						
21:3	21:4	V	21:6	21:9				
21:10	22:8	R, V	21:6	21:9				
22:21	23:13	R, P, F, NE	22:9	22:20	R			
23:22	24:1	R, P, F						
24:6	24:11	V	24:12	24:20	R, V, SP			
24:21	25:5	F, V						
25:7	25:7	V						
25:9	25:16	V						
26:18	26:25	M, V, Cmpd	25:18; 26:13	26:2; 26:17	R, V R, V	26:3 26:3	26:12 26:12	C
27:12	28:1							
28:2	28:3	M						

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
28:5	28:17	V						
28:18	28:19	V, NE						
28:21	29:4	Cmpd, PK						
29:6	29:11							
34:1	34:15	R, P, C, V						
36:22	37:6	R, P	35:22 35:25 37:9 38:11	35:23 36:8 37:17 38:22	R, P, V, NR, BSE R, P, V, NR, BSE R, P, V, NR, BSE R, P, V, NR, BSE			
37:7	37:7	R, P, C	35:22 35:25 37:9 38:11	35:23 36:8 37:17 38:22	R, P, V, NR, BSE R, P, V, NR, BSE R, P, V, NR, BSE R, P, V, NR, BSE			
37:25	38:2	R, P, C	35:22 35:25 37:9 38:11	35:23 36:8 37:17 38:22	R, P, V, NR, BSE R, P, V, NR, BSE R, P, V, NR, BSE R, P, V, NR, BSE			
39:23	40:1	F	38:23 39:10	39:6 39:12	R, V, NR, BSE R, V, NR, BSE			
40:12	41:3	PK, F, Spec, V						

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
41:8	41:23							
42:4	42:15	M						
43:4	43:7	M						
43:10	43:13	F						
43:15	44:3	PK, V						
44:13	44:13	V	44:17 48:7	44:21 48:15	R, V R, V, NR, BSE, P			
44:15	44:16		44:17	44:21				
45:22	46:6	R, C, V						
46:16	46:18	C, M, V, Arg						
46:21	47:1	R, C	48:7	48:15	R, M, P			
47:2	47:3	R, C, V	48:7	48:15	R, M, P			
47:5	47:9	C, R, V	48:7	48:15	R, M, P			
47:11	47:11		48:7	48:15	R, M, P			
48:17	49:3	R, C, V	49:13	49:19	V, M			
51: 6	51:8	P	50:22	51:5	R, F, PK, V			
54:16	54:18	R, P						
54:22	55:3	R, P, C	55:4	55:14	R, F, V, NR, BSE			
55:20	55:22	R, P, C, IC	55:23	56:3	R, NR, BSE			

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
56:10	56:12	R, P, C						
56:14	56:17	R, P, C						
56:25	57:5	P, C, PK						
58:16	58:18	P, C						
59:7	59:14	V						
59:16	60:10							
60:21	60:23	V, LC, F						
61:1	61:4	V, F						
61:6	61:19	V, LC, F, PK, Spec						
62:12	62:13	LC						
62:16	63:4	V						
63:13	63:25	V						
64:13	64:14	V						
64:16	65:11	R, V	65:12 65:14	65:12 65:17	V, M, R, NR, BSE V, M, R, NR, BSE			
66:8	67:1	R, P, PK, Spec	67:2	62:3	R, NR, BSE			
67:4	67:19	R, P	68:11 68:14 69:11	68:12 69:4 69:12	R, V R, V R, V R, V	67:24 67:24 67:24	68:10 68:10 68:10	C, V, M

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			69:14	69:16	R, V	67:24	68:10	
72:6	72:12	R, P						
73:3	73:6	R, P, Cmpd						
73:8	73:13	R, P	73:19	73:25	R, V	73:14 73:17	73:15 73:18	R, C, P, F, NE, A
73:8	73:13	R, P	74:3	74:13	R, V	73:14 73:17	73:15 73:18	R, C, P, F, NE, A
74:22	74:25	R, P						
76:6	76:8	F, PK, Spec, V, LC						
76:15	77:15	F, PK, Spec						
77:19	77:25	V, LC						
78:3	78:4	R, P						
78:9	79:5	M, V, F, PK, Spec						
79:7	79:18	F, PK, Spec, C						
79:20	80:8	V, LC						
80:11	80:11							
82:2	82:17	R, F, PK, Spec						
82:19	82:22	F, PK, Spec, V						
82:25	83:5							

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
85:2	85:8	F, PK, Spec						
85:10	85:15	F, PK, Spec						
87:15	87:16	R, F, V	87:19	87:25	R, V, P	88:1 88:3	88:1 88:3	R, C
87:18	87:18	R, F, V	87:19	87:25	R, V, P	88:1 88:3	88:1 88:3	R, C
88:5	88:20	R, P, M, V						
88:23	89:6	R, P						
89:12	89:14	R, F, LC						
89:16	89:22	R, F, PK, Spec						
90:4	90:13	R, C	91:5	95:11	R, V, PK, NT, LC, F, C, IC, H, P, AT			
91:21	91:24	R, F, LC						
92:2	92:4	R, F	92:5 92:7 92:15	92:5 92:13 92:16	R, V, F, LC, P R, V, F, LC, P R, V, F, LC, P			
93:5	93:12							
96:12	96:14							
96:22	96:25							
97:2	97:2							

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
97:5	97:10	R, P						
98:14	98:16	R, P						
99:2	99:5	R, P						
99:15	99:18	R, P, F, LC						
99:21	99:23	R, P						
100:15	100:18	R, P						
100:25	101:8	R, P, F, LC						
101:11	101:11	R, P	101:12 101:16	101:13 101:18	LC, R, V LC, R, V			
101:19	102:11	R, P, C	101:12 101:16	101:13 101:18	LC, R, V LC, R, V			
103:8	103:12	R, P, F, C						
103:14	103:23	R, P, F, LC, PK, C						
104:1	104:3	R, P, F, LC, PK, C						
104:5	104:5	R, P, C						
105:13	105:17	R, P, C						
105:22	105:22	R, P, F, LC, PK, C						
105:25	106:2	R, P, F, LC, PK, C						
106:12	106:19	R, P, F, LC, PK, C	108:4	108:12	R, V, NR, BSE			

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			108:18	109:6	R, V, NR, BSE			
106:22	106:22	R, P, C	108:4 108:18	108:12 109:6	R, V, NR, BSE R, V, NR, BSE			
108:14	108:17	R, P, C	108:18	109:6	R, V, PK, NR, BSE			
111:22	112:14	F, LC, PK						
115:20	115:21	R, F, LC, PK, V						
115:24	115:24	R						
117:4	117:12	R						
117:19	117:19	F						
117:21	118:2							
118:7	118:23	IC						
122:10	122:14	F, PK, Spec, IC						
112:16	123:12	F, LC, PK, V, AT, M						
124:18	124:21	F, PK, Spec						
125:5	125:22	F, PK, Spec						
126:3	127:13	F, PK, MD						
128:10	128:13	F, PK, Spec, M, Arg						
128:15	128:17	F, PK, Spec, Arg						

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
128:19	130:1	F, PK, Spec, Arg, C						
130:3	130:7	F, PK, Spec, C						
130:9	131:18	F, PK, Spec, V, C						
131:20	131:24	F, PK, Spec, V, C						
132:2	132:8	F, V, C	132:9 132:14	132:11 133:1	V, M, R, NR, BSE V, M, R, NR, BSE			
133:10	133:11	F, PK, Spec	133:17 133:22	133:20 133:24	V, R, NR, BSE V, R, NR, BSE			
133:13	133:16	F, PK, Spec	133:17 133:22	133:20 133:24	V, R, NR, BSE V, R, NR, BSE			
135:8	135:9	V	135:22 136:16	135:25 136:21	R, F R, F			
135:11	135:21		135:22 136:16	135:25 136:21	R, F R, F			
136:1	136:6		135:22 136:16	135:25 136:21	R, F R, F			
136:23	137:8		137:9	137:11	R, F			
137:12	138:5	F, MD						
138:8	138:13	F, MD, V						
138:16	139:8	F, MD, V	139:9	139:10	V, R, F			

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			139:13	139:18	V, R, F			
141:13	141:17	V, NE, Cmpd, C						
141:20	142:10	C	142:11	142:13	R, V			
142:14	143:10	C	142:11	142:13	R, S, V			
145:24	145:25	F, PK, Spec, V	146:5	146:15	R, V			
			147:5	147:15	R, V			
146:2	146:4	F, PK, Spec	146:5	146:15	R, V			
			147:5	147:15	R, V			
150:22	151:3		45:2	45:10	R, F, V, NR, BSE			
			151:4	151:11	R, F, V			
151:12	152:7	R, P, M	151:4	151:11	R, F, V			
			152:8	152:8	R, F, V			
			152:10	152:10	R, F, V			
152:11	152:17	R, P	152:8	152:8	R, F, V			
			152:10	152:10	R, F, V			
152:23	152:25	F, M, V, LC	153:4	153:17	R, F, V			
153:3	153:3		153:4	153:17	R, F, V			
153:18	153:20	F, M, V, ML	153:4	153:17	R, F, V			
153:23	153:23	F, V, ML						
155:13	155:16	F, V, ML	155:22	156:7	M, V, R, F			

John Keane (December 12, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
155:18	155:21	F, PK, V, ML	155:22	156:7	M, V, R, F			
156:18	157:3	V, ML	162:7 162:18	162:16 163:14	M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP			
157:5	158:16	F, PK, Spec, ML	162:7 162:18	162:16 163:14	M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP			
158:18	158:19	V, ML	162:7 162:18	162:16 163:14	M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP			
158:21	158:25	ML	159:15 162:7 162:18	160:13 162:16 162:18	M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP			
159:1	159:14	Cmpd, ML	159:15 162:7 162:18	160:13 162:16 162:18	M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP M, P, F, NR, BSE, SP			

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Matthew Levin (January 22, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
7:18	7:20							
9:10	9:13							
10:4	10:14							
10:18	11:20							
14:10	14:11							
14:16	14:19							
22:4	22:15		28:2;	28:15;	IC; F; V, SP, PK	54:12 54:19 126:3	54:16 54:21 126:10	IC, IN, R, P
			44:12;	44:18;	IC; V; PK; Compd; SP; NE; F; R; P	54:12 54:19	54:16 54:21	IC, IN, R, P
			44:25;	44:25;	IC; V; PK; Compd; SP; NE; F; R; P	54:12 54:19	54:16 54:21	IC, IN, R, P
			45:2;	45:10;	V; R; F	54:12 54:19	54:16 54:21	IC, IN, R, P
			56:2;	56:5;	IC; V; Arg; LC; F;	54:12	54:16	IC, IN, R, P

Matthew Levin (January 22, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
					SP; NE; P	54:19	54:21	
			56:9;	56:9;	IC; V; Arg; LC; F; SP; NE; P	54:12 54:19	54:16 54:21	IC, IN, R, P
			67:10;	67:12;				
			67:14;	68:6;	IC; 1002			
			68:18;	69:14;	M; F; NE; PK; SP; IC	69:15	69:20	
			69:21;	70:5;	V			
			70:19;	70:24;	IC; SP; V; F	54:12 54:19 71:14 71:17	54:16 54:21 71:15 71:18	IC, IN, R, P
			71:2;	71:2;	IC; SP; V; F	54:12 54:19 71:14 71:17	54:16 54:21 71:15 71:18	IC, IN, R, P
			71:4;	71:6;	IC; F; V; SP; PK	54:12 54:19 71:14 71:17	54:16 54:21 71:15 71:18	IC, IN, R, P
			71:12;	71:12;	IC; F; V; SP; PK	54:12	54:16	52:12-16, 54:19-

Matthew Levin (January 22, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						54:19 71:14 71:17	54:21 71:15 71:18	
			71:20;	71:22;		54:12 54:19 71:14 71:17	54:16 54:21 71:15 71:18	
			72:2;	72:2;		54:12 54:19 71:14 71:17	54:16 54:21 71:15 71:18	
			97:18	98:21	IC; PK; SP; LD	54:12 54:19 98:22	54:16 54:21 99:2	52:12-16, 54:19-21: IC, IN, R, P
27:23	28:1							
126:3	126:10		126:11	126:18	F; V, SP, PK	126:3	126:10	

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Todd M. Long (January 31, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
8:10	8:21							
59:16	59:21	In	59:9	59:15	PK; IC	59:22	59:22	C, PK, R, P, V
						59:25	60:6	
						60:12	60:13	
						60:16	60:19	
			61:13	61:17	PK; IC	59:22	59:22	C, PK, R, P, V
						59:25	60:6	
						60:12	60:13	
						60:16	60:19	
121:14	121:18	In	120:15	121:10	NR			
			121:12	121:13	NR			
121:20	121:25	In	120:15	121:10	NR			
			121:12	121:13	NR			
135:7	137:11	AT, R, P, C						

Todd M. Long (January 31, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
135:13	135:13	Subsumed by above (135:7-11)						
135:15	135:24	Subsumed by above (135:7-11)						
143:18	145:12	In, R, P, C	143:15	143:17				
145:15	145:18	In, R, P, C	143:15	143:17				
153:19	153:23	R, P, C						
154:10	154:19	R, P, C						
155:11	155:14	R, P, C						
155:16	155:20	R, P, C, Spec						
155:23	156:2	R, P, C, Spec						
156:5	156:6	R, P, C, Spec						
156:7	156:7	R, P, C						
156:9	156:13	R, P, C						
156:16	156:16	R, P, C						
157:14	157:16	R, P, C, Spec	157:3	157:13	AT; NR			
157:19	157:20	R, P, C, Spec	157:3	157:13	AT; NR			
175:24	176:8	R, P, C, Spec						
176:17	176:25	R, P, C, Spec						

Todd M. Long (January 31, 2018)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
181:16	181:18	R, P, C						
182:15	182:18	R, P, C	182:8	182:14	AT; NR			
182:20	183:3	R, P, C	182:8	182:14	AT; NR			

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
21:12	21:21		6:17	6:18				
34:17	34:23		34:25	35:4				
			36:1	36:3				
86:9	86:21		87:25	88:7	F, NE, SP, ID	91:6 108.23	91:16 109:15	F, V, Spec
87:4	87:24	AT: 87:9-87:10	87:25	88:7	F, NE, SP, ID	91:6 108.23	91:16 109:15	F, V, Spec
92:13	93:5	ML: 92:13-92:25	92:5	92:12	V, ID	91:6 91:25	91:16 92:4	F, V, Spec
114:8	114:19	Spec, F, ML, P	113:22	113:25	ID, H, F, NE, SP, PK, M	114:2	114:2	
			114:4	114:7	ID, H, F, NE, SP, PK, M	114:2	114:2	
			114:20	114:23				
			115:10	115:13	H, F, SP, PK, ID	85:11 114:16 115:14	85:16 114:19 115:17	P, R, ML H
			116:22	118:2	F, NE, SP, PK, H, V, M, L, ID	115:18 115:23 117:7	115:20 115:25 117:8	F, V, Spec, C, PK F, V, Spec, C, PK
			118:18	118:20	ID, F, SP, PK	118:24	119:1	
			119:2	119:5	ID, F, SP, PK	118:24	119:1	
			144:5	144:11	ID, V, SP, PK, R	143:7 143:13 144:12	143:10 144:4 144:19	F, V, Spec F, V, Spec F, V, Spec

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						144:21 145:3	144:25 145:7	F, V, Spec F, V, Spec
167:18	169:4	F, P, ML, V, AT: 167:23-167:24	167:6	167:7	F, V, NE, F, SP			
			167:13	167:16	F, V, NE, F, SP, ID	167:18 167:25	167:22 169:4	F, V, Spec F, P, V, ML
			169:7	169:8	F, SP, PK, V			
			169:13	169:23	F, SP, PK, V			
			170:17	170:20	F, SP, PK, V, NE, P, ID	171:5	171:8	
			170:24	171:2	F, SP, PK, V, NE, P, ID	171:5	171:8	
			174:15	174:19	R, SP, V, ID	174:20	174:24	
			174:25	175:2	F, NE, SP, PK, ID	174:20	174:24	
			175:5	175:7	F, NE, SP, PK, ID	174:20	174:24	
			175:9	175:14	F, NE, SP, PK, V	174:20	174:24	
			176:25	177:4	F, M, NE, SP, PK, V			
			177:8	177:8	F, M, NE, SP, PK, V, ID	177:11 177:16	177:13 177:20	F, V, PK, Spec F, V, PK, Spec, P
187:1	187:25	F, Spec	176:25	177:4	F, M, NE, SP, PK, V			
			177:8	177:8	F, M, NE, SP, PK, V, ID	177:11 177:16	177:13 177:20	F, V, PK, Spec F, V, PK, Spec, P
188:1	188:13	F, Spec, C, AT: 188:5-188:7	176:25	177:4	F, M, NE, SP, PK, V			
			177:8	177:8	F, M, NE, SP, PK, V, ID	177:11 177:16	177:13 177:20	F, V, PK, Spec F, V, PK, Spec, P
207:18	208:9	V, AT: 208:3-	211:11	211:15	ID, NE, V, SP, PK,	211:16	211:21	F, Spec, R, P

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
		208:5; 207:18-207:19			F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			211:22	212:5	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			212:10	212:14	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			212:21	212:24				
210:8	210:15	F, Spec, Char	211:11	211:15	ID, NE, V, SP, PK, F	211:16 212:15 212:25 213:7 213:12	211:21 212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec, R, P F, Spec F, Spec F, Spec
			211:22	212:5	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			212:10	212:14	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			212:21	212:24				
212:15	212:20	F, Spec	211:11	211:15	ID, NE, V, SP, PK, F	211:16 212:15	211:21 212:20	F, Spec, R, P F, Spec, R, P

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						212:25 213:7 213:12	213:4 213:10 213:18	F, Spec F, Spec F, Spec
			211:22	212:5	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			212:10	212:14	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
212:25	213:18	F, Spec, AT: 213:5- 213:6	211:11	211:15	ID, NE, V, SP, PK, F	211:16 212:15 212:25 213:7 213:12	211:21 212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec, R, P F, Spec F, Spec F, Spec
			211:22	212:5	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			212:10	212:14	ID, NE, V, SP, PK, F	212:15 212:25 213:7 213:12	212:20 213:4 213:10 213:18	F, Spec, R, P F, Spec F, Spec F, Spec
			176:25	177:4	F, M, NE, SP, PK, V			
			177:8	177:8	F, M, NE, SP, PK, V, ID	177:11 177:16	177:13 177:20	F, V, PK, Spec F, V, PK, Spec, P
228:10	228:25	F, Spec	233:9	233:16	1002, F, Spec, PK	231:7	231:13	Spec, V

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						236:2 237:5	236:11 237:12	Spec, V Spec, V
			234:5	234:8	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			234:11	234:14	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			234:22	235:2	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			235:4	235:8	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			235:10	235:13	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			235:16	235:18	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
238:13	238:18	F, Spec, R, P, Char	233:9	233:16	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			234:5	234:8	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			234:11	234:14	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			234:22	235:2	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			235:4	235:8	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			235:10	235:13	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			235:16	235:18	1002, F, Spec, PK	231:7 236:2 237:5	231:13 236:11 237:12	Spec, V Spec, V Spec, V
			260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			261:25	262:5	M, V, R, P, F, SP,	261:6	261:9	F, Spec, R, V, C, IC

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
					PK, LC, Arg			
250:24	251:8	F, Spec, R, P, C, Char	249:23	250:6				
			260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			261:25	262:5	M, V, R, P, F, SP, PK, LC, Arg	261:6	261:9	F, Spec, R, V, C, IC
			263:25	264:5	F, SP	264:6	264:12	F, Spec, V
252:11	254:17	F, Spec, ML, R, P, C, Char, AT: 253:11-253:12	260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23	255:20 256:22 257:16 259:13 259:16 259:20 260:16	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						261:6	261:9	F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			261:25	262:5	M, V, R, P, F, SP, PK, LC, Arg	261:6	261:9	F, Spec, R, V, C, IC
255:8	255:20	F, Spec, R, P, C, Char	260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			261:25	262:5	M, V, R, P, F, SP, PK, LC, Arg	261:6	261:9	F, Spec, R, V, C, IC

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
255:25	256:22	F, Spec, ML, R, P, C, Char	260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			261:25	262:5	M, V, R, P, F, SP, PK, LC, Arg	261:6	261:9	F, Spec, R, V, C, IC
			263:25	264:5	F, SP	264:6	264:12	F, Spec, V
258:8	258:21	F, Spec, ML, R, P, C, H, Char	260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25	255:20 256:22	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						257:8 257:20 259:15 259:20 259:23 261:6	257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			261:25	262:5	M, V, R, P, F, SP, PK, LC, Arg	261:6	261:9	F, Spec, R, V, C, IC
			263:25	264:5	F, SP	264:6	264:12	F, Spec, V
279:23	281:4	Spec, P, F, AT: 280:7-280:8	279:13	279:22	R, SP, PK, NE, V, F, P, H, ID	279:23 280:9	280:6 281:4	Spec, P, F Spec, P, F, C
			281:22	281:25	R, NE, F, ID	281:5	281:21	Spec, P, F, C
			282:14	282:25	V			
			291:16	291:19	ID, SP, IO, 701, V, R, P, LC, F, NE, PK	291:14	291:15	Spec, F, V, IC
			291:23	292:4	ID, SP, IO, 701, V, R, P, LC, F, NE, PK	291:14	291:15	Spec, F, V, IC
			293:19	294:1	V, F, R, P, NE, SP, PK, LC			
284:14	288:25	F, Spec, P, C, AT: 284:19-284:21; 286:13-286:16; 287:2-287:3; 287:12-287:14; 287:22-287:24; 288:22-288:23	279:13	279:22	R, SP, PK, NE, V, F, P, H, ID	279:23 280:9	280:6 281:4	Spec, P, F Spec, P, F, C
			281:22	281:25	R, NE, F, ID	281:5	281:21	Spec, P, F, C
			282:14	282:25	V			
			291:16	291:19	ID, SP, IO, 701, V,	291:14	291:15	Spec, F, V, IC

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
					R, P, LC, F, NE, PK			
			291:23	292:4	ID, SP, IO, 701, V, R, P, LC, F, NE, PK	291:14	291:15	Spec, F, V, IC
			293:19	294:1	V, F, R, P, NE, SP, PK, LC			
303:24	304:21	F, H, Spec, R, P, C, Char	260:4	260:12	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			260:18	260:21	M, V, R, P, F, SP, PK, LC, Arg, ID	255:8 255:25 257:8 257:20 259:15 259:20 259:23 261:6	255:20 256:22 257:16 259:13 259:16 259:20 260:16 261:9	F, Spec, R, P, C, Char F, Spec, ML, R, P, C, Char F, Spec, R, P, C, Char F, Spec, ML, R, P, C, H, Char F, Spec, V, R R, F, V, R F, Spec, Char, R F, Spec, R, V, C, IC
			304:23	304:25				
			305:5	305:8				
341:12	341:20	Spec, R, Char, V	348:13	348:22	R, C, P, ID	349:22	349:24	
			348:25	349:21	R, C, P, ID	349:22	349:24	
			357:4	357:12	R, C, P			
			341:21	341:22	F, SP, PK			
			341:25	342:3	F, SP, PK			
342:13	342:16	Spec, R, V, F, Char	348:13	348:22	R, C, P, ID	349:22	349:24	

James Loveland (November 29, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			348:25	349:21	R, C, P, ID	349:22	349:24	
			357:4	357:12	R, C, P			
			342:17	343:9	F, SP, PK			
365:23	366:3	Spec, F, V, R, Char, AT: 345:24-366:1	366:14	366:16	V, SP, R, C, ID	365:23 366:2	365:23 366:3	Spec, F, V, R, Char Spec, F, V, R, Char
			366:18	366:19	V, SP, R, C, ID	365:23 366:2	365:23 366:3	Spec, F, V, R, Char Spec, F, V, R, Char

EagleView Technologies, Inc. et al. v. Xactware Solutions, Inc. et al.,
Case No. 15-cv-7025 (D.N.J.)

Defendants' Affirmative Deposition Designations, Plaintiff's Counter-Designations, and Defendants' Counter-Counter Designations, and Objections Thereto

Jason Pawlick (December 5, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
5:8	5:13							
7:1	7:11							
11:21	11:25							
12:2	12:12							
22:5	22:19							
29:6	29:10		29:11	29:25	SP, R	188:12	188:22	IC, F, R
30:12	30:23		30:24	31:2	V, PK, R			
34:21	35:14		34:11	34:20	V	34:21	35:14	
			97:5	97:16	ID, PK, F, A, Cmpd, SP, H	188:12	188:22	IC, F, R
			97:18	98:10	V, ID, PK, SP, F, A	188:12	188:22	IC, F, R
36:22	37:10							
39:6	39:20							
65:7	66:20	66:12-13-AT	66:21	66:24	ID, V, SP, PK	188:12	188:22	IC, F, R
111:13	111:17							
118:10	118:15							

Jason Pawlick (December 5, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
121:12	121:14		120:24	121:2	ID, M, H, V, F, 1002	120:12 120:16 120:20 188:12	120:13 120:17 120:22 188:22	188:12-188:22 - IC, F, R
			121:5	121:8	1002, H, V, F	120:12 120:16 120:20 188:12	120:13 120:17 120:22 188:22	188:12-188:22 - IC, F, R
			121:15	121:17		121:24	122:15	
			122:16	122:19	H, 1002	126:10	127:2	
			123:7	123:12	ID, 1002, H, V	126:10	127:2	
			124:1	124:4	H, 1002, V, Compd, PK	124:5 126:10	124:9 127:2	
			124:13	124:22	ID, V, H, 1002, F	126:10	127:2	
			127:14	127:16	1002, H, V, F			
			129:10	130:11	ID, R, PK, SP, V, LD	130:12 130:15 131:1 131:7 131:15	130:13 130:24 131:5 131:8 131:17	

Jason Pawlick (December 5, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
			153:11	153:18	ID, PK, F, A, 1002, H	153:1 153:24	153:5 154:1	R, PK
124:10	124:12		120:24	121:2	ID, M, H, V, F, 1002	120:16 120:20	120:17 120:22	
			121:5	121:8	1002, H, V, F	120:16 120:20 188:12	120:17 120:22 188:22	
			121:15	121:17		121:24	122:15	
			122:16	122:19	H, 1002	126:10	127:2	IC, C, P, R, F
			123:7	123:12	ID, 1002, H, V	126:10	127:2	
			124:1	124:4	H, 1002, V, Cmpd, PK	124:5	124:9	
			124:13	124:22	ID, V, H, 1002, F	126:10	127:2	
			127:14	127:16	1002, H, V, F			
			129:10	130:11	ID, R, PK, SP, V, LD	130:12 130:15 131:1 131:7 131:15	130:13 130:24 131:5 131:8 131:17	
			153:11	153:18	ID, PK, F, A	152:25	153:5	IC, In, M, P, R

Jason Pawlick (December 5, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						153:24	154:1	
126:10	127:2		120:24	121:2	ID, M, H, V, F, 1002	120:12 120:16 120:20 188:12	120:13 120:17 120:22 188:22	
			121:5	121:8	1002, H, V, F	120:12 120:16 120:20 188:12	120:13 120:17 120:22 188:22	IC, C, P, R, F
			121:15	121:17		120:12 120:16 120:20 188:12	120:13 120:17 120:22 188:22	IC, C, P, R, F
			122:16	122:19	H, 1002	126:10	127:2	IC, C, P, R, F
			123:7	123:12	ID, 1002, H, V	126:10	127:2	IC, C, P, R, F
			124:1	124:4	H, 1002, V, Cmpd, PK	124:5	124:9	IC, C, P, R, F, H
			124:13	124:22	ID, V, H, 1002, F	126:10	127:2	IC, C, P, R, F
			127:14	127:16	1002, H, V, F			
			129:10	130:11	ID, R, PK, SP, V, LD	130:12 130:15	130:13 130:24	R, C, IC

Jason Pawlick (December 5, 2017)								
Defendants' Designations		Plaintiff's Objections	Plaintiff's Counter-Designations		Defendants' Objections to Plaintiff's Counter-Designations	Defendants' Counter-Counter Designations		Plaintiff's Objections to Defendants' Counter-Counter Designations
Line Start	Line End		Line Start	Line End		Line Start	Line End	
						131:1 131:7 131:15	131:5 131:8 131:17	
			153:11	153:18	ID, PK, F, A	152:25 153:24	153:5 154:1	R, PK
183:8	183:20	R, F, V	183:21	184:2		188:12	188:22	IC, F, R
184:3	184:5	R, F, V	183:21	184:2		188:12	188:22	IC, F, R
184:7	184:8	R, F, V	183:21	184:2		188:12	188:22	IC, F, R
193:5	193:25	193:5-13-C	194:1	194:7		188:12	188:22	IC, F, R
			169:3	169:14	ID, R, Compd, V, R	168:4 188:12	169:2 188:22	188:12-22 - IC, F, R
			169:16	169:18		188:12	188:22	188:12-22 - IC, F, R

Plaintiff's Objections Key

Eagle View Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.

Case No. 15-cv-07025 (RBK/JS) (Dist. N.J.)

ABBREV.	OBJECTION
A	Authentication or Identification (FRE 901) The requirement of authentication or identification as a condition precedent to admissibility is satisfied by evidence sufficient to support a finding that the matter in question is what its proponent claims.
Arg	Argumentative
AT	Attorney Objections Not Removed
BS	Beyond the Scope of Direct / Cross / Redirect Examination
30(b)(6)	Beyond the Scope of the Rule 30(b)(6) Deposition Topic
C	Cumulative, Duplicative, Wasteful or Undue Delay (FRE 403) Although relevant, evidence may be excluded if its probative value is substantially outweighed by considerations of undue delay, waste of time, or needless presentation of duplicative and/or cumulative evidence.
Char	Improper Character Evidence (FRE 404)
Cmpd	Compound
Dem Only	Demonstrative / Should Not Be Admitted Into Evidence
D	Not Produced During Discovery
F	Lack of Foundation (FRE 602) Objectionable because a witness may not testify to a matter unless evidence is introduced sufficient to support a finding that the witness has personal knowledge of the matter.
H	Hearsay Rule (FRE 802) Hearsay is not admissible except as provided by these rules or by other rules prescribed by the Supreme Court pursuant to statutory authority or by Act of Congress.

ABBREV.	OBJECTION
I	<p>Incomplete Document (FRE 106)</p> <p>Objectionable because document is incomplete and the introduction of the remaining portions or related documents ought, in fairness, to be considered contemporaneously with it.</p>
IC	Improper Designation / Counter Designation (FRE 106: FRCP 32(a)(6))
ID	Incomplete Document (FRE 106)
In	Incomplete Testimony (FRE 106; FRCP 32(a)(6))
L	Lack of Personal Knowledge or Competency (FRE 602)
LA	Limited Admissibility (Admissible for Some Purposes but Not Others) (FRE 105)
LC	Legal Conclusion
LD	Leading (FRE 611)
LF	Lack of Foundation (FRE 103, 104 and/or 105)
M	Misleading/Mischaracterizes Prior Testimony (FRE 401-403, 611)
MD	Mischaracterizes Underlying. Document (FRE 401-403, 611)
ML	Subject to Motion In Limine
NE	Assumes Facts Not In Evidence
NR	Nonresponsive
NT	Not Testimony
O	Improper Lay or Expert Opinion (FRE 701-703)
OC	Offer to Compromise, Settlement (FRE 408)

ABBREV.	OBJECTION
P	<p>Prejudicial, Confusing, Vague and/or Misleading (FRE 403)</p> <p>Although relevant, evidence may be excluded if its probative value is substantially outweighed by the danger of unfair prejudice, confusion of the issues, or misleading the jury, or by considerations of undue delay, waste of time, or needless presentation of cumulative evidence.</p>
PD	<p>Post Dated Filing Date (FRE 105)</p> <p>If post-dated evidence is admitted as to one purpose but not admissible as for another purpose (e.g., for obviousness analysis), the court, upon request, shall restrict the evidence to its proper scope and instruct the jury accordingly.</p>
PK	<p>Lack of Personal Knowledge (FRE 602)</p> <p>Objectionable because lack of personal knowledge makes the witness incompetent to testify about particular facts.</p>
R	<p>Relevance (FRE 401, 402)</p> <p>All relevant evidence is admissible, except as otherwise provided by the Constitution of the United States, by Act of Congress, by these rules, or by other rules prescribed by the Supreme Court pursuant to statutory authority. Evidence which is not relevant is not admissible.</p>
Spec	<p>Calls for Speculation (FRE 602)</p>
S	<p>Summaries (FRE 1006)</p> <p>The party relying on the summary must establish its accuracy to the court's satisfaction.</p> <p><i>See Graham, Handbook of Federal Evidence § 1006.1 (5th ed. 2001). United States v. Pelullo, 964 F.2d 193, 204 (3d Cir. 1992) ("It is well established that summary evidence is admissible under Rule 1006 only if the underlying materials upon which the summary is based are admissible.").</i></p>
U	<p>Untimely / Never Produced (FRCP 26, 37)</p>
V	<p>Vague / Ambiguous/Overbroad (FRE 611)</p>
W	<p>Privileged / Work Product (FRE 501/502)</p>
X	<p>Exhibit has not been provided, the copy provided is illegible, and/or the entry includes multiple documents.</p>

ABBREV.	OBJECTION
Y	Wrong Document Identified or Incorrectly Described
105	<p>Limited Admissibility (FRE 105)</p> <p>When evidence which is admissible as to one party or for one purpose but not admissible as to another party or for another purpose is admitted, the court, upon request, shall restrict the evidence to its proper scope and instruct the jury accordingly.</p>
701	<p>Improper Lay Opinion Testimony (FRE 701)</p> <p>If a witness is not testifying as an expert, testimony in the form of an opinion is limited as provided by this rule.</p>
1002	<p>Best Evidence (FRE 1002, 1003, 1004)</p> <p>An original writing, recording, or photograph is required in order to prove its content unless these rules or a federal statute provides otherwise.</p>

Eagle View Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.
Case No. 15-cv-07025 (RBK/JS) (D.N.J.)

Defendants' Objection Key

ABBREV.	OBJECTION	RULE / EXPLANATION
A	Authentication or Identification (FRE 901)	The requirement of authentication or identification as a condition precedent to admissibility is satisfied by evidence sufficient to support a finding that the matter in question is what its proponent claims.
Arg	Argumentative	
AT	Attorney Objections Not Removed	
BSE	Beyond Scope of Direct / Cross / Or Redirect Examination	Objectionable because the testimony exceeds the scope of the direct, cross, or redirect examination.
BSS	Beyond Scope of Subpoena	Objectionable because the testimony exceeds the scope of the subpoena
BST	Beyond Scope of Rule 30(b)(6) Deposition Topic	Objectionable because the testimony exceeds the scope for which the witness was designated to testify pursuant Rule 30(b)(6).
C	Cumulative, Duplicative, Wasteful or Undue Delay (FRE 403)	Although relevant, evidence may be excluded if its probative value is substantially outweighed by considerations of undue delay, waste of time, or needless presentation of duplicative and/or cumulative evidence.
Char	Improper Character Evidence (FRE 404)	
Cmpd	Compound	
D	Not Produced During Discovery	
F	Lack of Foundation (FRE 602)	Objectionable because a witness may not testify to a matter unless evidence is introduced sufficient to support a finding that the witness has personal knowledge of the matter.
H	Hearsay Rule (FRE 802)	Hearsay is not admissible except as provided by these rules or by other rules prescribed by the Supreme Court pursuant to statutory authority or by Act of Congress.
I	Incomplete Document (FRE 106)	Objectionable because document is incomplete and the introduction of the remaining portions or related documents ought, in fairness, to be considered contemporaneously with it.
ID	Improper/Incomplete Designation (FRCP 32(a)(6))	Objectionable because additional parts of the testimony in fairness should be considered with the part of the testimony designated.
IC	Improper/Incomplete Counter Designation (FRCP 32(a)(6))	Objectionable because additional parts of the testimony in fairness should be considered with the part of the testimony designated.
IO	Improper Lay or Expert Opinion (FRE 701-703)	Objectionable because the testimony is outside the scope of proper lay or expert testimony.
IP	Improper Use of Deposition Testimony (FRCP 32)	Objectionable because the designation is inconsistent with the proper use of deposition testimony pursuant to FRCP 32.
IDe	Improper Designation of Witness who will be Called Live	Objectionable because the witness who gave the designated testimony will be called to testify at trial.
LC	Legal Conclusion (FRE 403)	Objectionable because witness testimony constituting a legal conclusion creates a danger of unfair prejudice, confusing the issues, misleading

Eagle View Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.
Case No. 15-cv-07025 (RBK/JS) (D.N.J.)

Defendants' Objection Key

		the jury, undue delay, or wasting time.
LD	Leading (FRE 611)	Objectionable because leading questions should not be used on direct examination except as necessary to develop the witness's testimony.
M	Mischaracterizes Prior Testimony (FRE 401-403, 611)	Objectionable because the designation includes mischaracterization of prior testimony, as a result the testimony lacks relevance and creates a danger of unfair prejudice, confusing the issues, misleading the jury, undue delay, or wasting time.
MD	Mischaracterizes Underlying Document	Objectionable because the designation includes mischaracterization of an underlying document, as a result the testimony lacks relevance and creates a danger of unfair prejudice, confusing the issues, misleading the jury, undue delay, or wasting time.
NE	Assumes Facts Not in Evidence	Objectionable because the question assumes facts not in evidence.
NR	Nonresponsive	Objectionable because the designated testimony is not responsive to the question.
NT	Not Testimony	Objectionable because the designated material is not testimonial.
OS	Offer of Settlement (FRE 408)	Evidence of an offer of consideration to compromise or attempt to compromise a claim, or conduct or a statement made during compromise negotiations about the claim, is not admissible.
P	Prejudicial, Confusing, Vague and/or Misleading (FRE 403)	Although relevant, evidence may be excluded if its probative value is substantially outweighed by the danger of unfair prejudice, confusion of the issues, or misleading the jury, or by considerations of undue delay, waste of time, or needless presentation of cumulative evidence.
PK	Lack of Personal Knowledge (FRE 602)	Objectionable because lack of personal knowledge makes the witness incompetent to testify about particular facts.
PR	Privilege (FRE 501-502)	The evidence is subject to a claim of attorney-client privilege or other privilege.
R	Relevance (FRE 401, 402)	All relevant evidence is admissible, except as otherwise provided by the Constitution of the United States, by Act of Congress, by these rules, or by other rules prescribed by the Supreme Court pursuant to statutory authority. Evidence that is not relevant is not admissible.
SP	Calls for Speculation	Objectionable because the designation includes a question calling for speculation and/or speculation as a result the testimony lacks relevance and creates a danger of unfair prejudice, confusing the issues, misleading the jury, undue delay, or wasting time.
S	Summaries (FRE 1006)	The party relying on the summary must establish its accuracy to the court's satisfaction. <i>See</i> Graham, Handbook of Federal Evidence § 1006.1 (5th ed. 2001). <i>United States v. Pelullo</i> , 964 F.2d 193, 204 (3d Cir. 1992) ("It is well established that summary evidence is admissible under Rule 1006 only if the underlying materials upon which the summary is based are admissible.").
V	Vague, Ambiguous or Overbroad (FRE 611)	
105	Limited Admissibility (FRE 105)	When evidence that is admissible as to one party or for one purpose but not admissible as to another party or for another purpose is admitted, the court, upon request, shall restrict the evidence to its proper scope and instruct the jury accordingly.
701	Improper Lay Opinion	If a witness is not testifying as an expert, testimony in the form of an

Eagle View Technologies, Inc. et al. v. Xactware Solutions, Inc. et. al.
Case No. 15-cv-07025 (RBK/JS) (D.N.J.)

Defendants' Objection Key

	Testimony (FRE 701)	opinion is limited as provided by this rule.
1002	Best Evidence (FRE 1002)	An original writing, recording, or photograph is required in order to prove its content unless the rules or a federal statute provide otherwise.
PD	Post Dated Filing Date (FRE 105)	If post-dated evidence is admitted as to one purpose but not admissible as for another purpose (<i>e.g.</i> , for obviousness analysis), the court, upon request, shall restrict the evidence to its proper scope and instruct the jury accordingly.
Badgering	Badgering the Witness	Inappropriate badgering of the witness.
X		Exhibit has not been provided, the copy provided is illegible, and/or the entry includes multiple documents.
Y	Wrong Document Identified or Incorrect Description of Document	
MIL	Motion in Limine	Subject to motion in limine.

